HeartSciences (NASDAQ:HSCS) Releases Earnings Results, Misses Estimates By $0.14 EPS

HeartSciences (NASDAQ:HSCS) announced its quarterly earnings results on Monday. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.14), FiscalAI reports. The firm had revenue of $0.00 million during the quarter, compared to analysts’ expectations of $0.10 million.

HeartSciences Price Performance

Shares of NASDAQ:HSCS traded up $0.15 during midday trading on Monday, hitting $3.54. The company had a trading volume of 76,861 shares, compared to its average volume of 848,389. HeartSciences has a 12-month low of $1.63 and a 12-month high of $4.35. The company has a fifty day moving average of $2.67 and a two-hundred day moving average of $2.38. The company has a market cap of $13.81 million, a price-to-earnings ratio of -0.90 and a beta of 1.85.

Analyst Ratings Changes

HSCS has been the subject of several research reports. Wall Street Zen raised shares of HeartSciences to a “sell” rating in a report on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of HeartSciences in a research note on Wednesday, June 24th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $8.00.

About HeartSciences

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.